PMID- 16541965
OWN - NLM
STAT- MEDLINE
DCOM- 20060801
LR  - 20161020
IS  - 1088-5412 (Print)
IS  - 1088-5412 (Linking)
VI  - 26
IP  - 6
DP  - 2005 Nov-Dec
TI  - Unanswered questions and warnings involving anti-immunoglobulin E therapy based 
      on 2-year observation of clinical experience.
PG  - 435-9
AB  - The relatively rapid development and deployment of a clinically useful monoclonal 
      antibody omalizumab has produced a number of questions still not answered despite 
      massive research and many clinical trials. The mechanism of action as 
      down-regulation of FceR1 receptors in the presence of low free immunoglobulin E 
      (IgE) is incomplete. Some severe allergic asthmatic patients respond almost 
      immediately, others take months, and some never respond. No accounting for the 
      possible antigen sweeping by the complexes of IgG-IgE has been reported. Skin 
      tests may remain positive for much longer than reported, raising the possibility 
      of anaphylaxis with concomitant specific immunotherapy. Two cases of anaphylaxis 
      to specific immunotherapy while being "covered" with anti-IgE are reported. Total 
      IgE levels do not always rise as expected, six cases of static IgE levels in 
      responders are reported. Total IgE levels do not dependably predict usefulness. 
      Current guidelines for anti-IgE use in asthmatic patients may require 
      reexamination as data from broad clinical experience are gathered.
FAU - Lanier, Bob Q
AU  - Lanier BQ
AD  - Department of Pediatrics, University of North Texas, Fort Worth, Texas 76132, 
      USA.
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - Allergy Asthma Proc
JT  - Allergy and asthma proceedings
JID - 9603640
RN  - 0 (Antibodies, Anti-Idiotypic)
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (anti-IgE antibodies)
RN  - 2P471X1Z11 (Omalizumab)
RN  - 37341-29-0 (Immunoglobulin E)
SB  - IM
MH  - Adult
MH  - Antibodies, Anti-Idiotypic/adverse effects/*therapeutic use
MH  - Antibodies, Monoclonal/adverse effects/*therapeutic use
MH  - Antibodies, Monoclonal, Humanized
MH  - Asthma/*drug therapy/immunology/physiopathology
MH  - Female
MH  - Humans
MH  - Immunoglobulin E/analysis
MH  - Male
MH  - Middle Aged
MH  - Omalizumab
RF  - 22
EDAT- 2006/03/18 09:00
MHDA- 2006/08/02 09:00
CRDT- 2006/03/18 09:00
PHST- 2006/03/18 09:00 [pubmed]
PHST- 2006/08/02 09:00 [medline]
PHST- 2006/03/18 09:00 [entrez]
PST - ppublish
SO  - Allergy Asthma Proc. 2005 Nov-Dec;26(6):435-9.